Bauml J et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. ASCO 2021;Abstract 9006.

Benayed R. et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res 2019;25(15):4712-22. Abstract

Besse B et al. Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 9065.

Curigliano G et al. Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial. ASCO 2021;Abstract 9089.

Jordan EJ et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017;7(6):596-609. Abstract

Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2021;[Online ahead of print]. Abstract

Soria JC et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113-25. Abstract

Tsuboi M et al. Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence. ESMO 2020;Abstract LBA1.

Wu YL et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020;383(18):1711-23. Abstract

Yu HA et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19(8):2240-7. Abstract

Zhou C et al. Mobocertinib in NSCLC with EGFR exon 20 insertions: Results from EXCLAIM and pooled platinum-pretreated patient populations. IASLC/WCLC 2020;Abstract OA04.03.